Site icon LucidQuest Ventures

ELCC 2026 Preview: Key Competitive Shifts in Lung Cancer

ELCC 2026 lung cancer conference preview covering NSCLC, SCLC, emerging therapies and artificial intelligence.

ELCC 2026_Preview_by_LucidQuest

ELCC 2026 at a glance

ELCC 2026 highlights key lung cancer treatment trends, from emerging therapies and treatment sequencing in NSCLC and SCLC to advances in precision oncology. The conference also explores how artificial intelligence and machine learning could improve early detection, biomarker assessment, immunotherapy prediction and clinical decision-making.

πŸ“… Build your schedule around the topics that matter most.

πŸ“₯ Download the ELCC 2026_Preview_by_LucidQuest

ELCC 2026: Key Developments in Lung Cancer Treatment

Advanced NSCLC: Bispecifics, ADCs, and Post-IO Strategies

Bispecifics, ADCs, and post-IO strategies are set to compete on biomarkers, HRQoL, convenience, and real-world relevance.

Early-Stage and Stage III NSCLC

Long-term survival, pCR/MRD depth, and molecular context are increasingly guiding perioperative and post-cCRT care.

Oncogene-Driven NSCLC

EGFR, ALK, ROS1, and RET strategies are moving toward earlier intensification, smarter sequencing, and resistance-matched combinations.

SCLC and LCNEC

Survival tails, bispecifics, and DLL3-directed intensification are expected to shape the next first-line competitive phase.

Biomarkers and Supportive Care

Screening, biomarker delivery, trial access, and ePRO tools remain central to better lung cancer care.

Artificial Intelligence and Machine Learning at ELCC 2026

Early Detection

XGBoost risk modeling reached AUC 90.2% and sensitivity 72.2%.

MDT Automation

A lung cancer LLM processed 849 MDT cases over 13-fold faster, with 96.7% extraction accuracy.

IO Prediction

APOLLO11 models reached AUC 0.80 for poor survival and 0.85 for long-term survival.

Real-World Machine Learning

Gradient boosting and SVM models highlighted practical IO resistance prediction from routine lab markers.

Pathology AI

LATTICe-A outperformed IASLC grade for prognosis across 1,007 cases.

Download the ELCC 2026 Preview Report and Planner

Download our ELCC 2026 preview report for deeper analysis of emerging lung cancer therapies, treatment sequencing, biomarker-driven strategies and AI applications in oncology.

πŸ“… Build your schedule around the sessions that matter most.

πŸ“₯ Download the ELCC 2026_Preview_by_LucidQuest

Contact usΒ for end-to-end conference coverage.

Exit mobile version